Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Eisai Inc.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02019264CT.gov A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cardiovascular Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lorcaserin (this asset) | Eisai Inc. | Approved | B · 63 |
| Aspirin | AstraZeneca | P4 | BBB |
| Liraglutide | University of Sao Paulo General Hospital | P4 | BBB |
| Atorvastatin | Duke University | P4 | BBB |
| Rosuvastatin | Nanjing First Hospital, Nanjing Medical University | P4 | BBB |
| Simvastatin | McMaster University | P4 | BBB |
| Ramifentanyl | Helse Fonna | P4 | BBB |
| Degarelix | Rabin Medical Center | P4 | BBB |
| Hydrochlorothiazide | Tehran University of Medical Sciences | P4 | BBB |
+42 more in the Cardiovascular Disorder cohort
Other indications for Lorcaserin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Obesity Disorder | — | P4 | BB · 66 |
| Schizoaffective Disorder | — | P4 | B · 60 |
| Nicotine Dependence | — | P2/3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lorcaserin in Cardiovascular Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lorcaserin-cardiovascular-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →